- About us
- About Vaccines
- Media centre
- Become a member
Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.
Effective vaccination programmes ease pressure on budgets and allow resources to focus on other healthcare areas and medical innovation
Vaccination at the Heart of Public Health. Vaccines Europe calls on EU policy-makers to develop a comprehensive vaccination strategy through five core policy asks.
As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe as well as small and medium sized enterprises.
Find out more about our services, the opportunites we offer and how to become a member.
Vaccine-preventable diseases have significant impacts on adult mortality, health and quality of life. Adult vaccination has been given less emphasis than other health priorities and its benefits to societies are not as well recognised. Current national vaccination recommendations focusing on childhood vaccines need to be expanded to ensure opportunities for other population groups, such as adults and particularly those ages 65 and older, who are at highest risk for many infections.
Vaccines Europe calls on public health authorities to set up a structured dialogue/platform bringing together all stakeholders with the objective of establishing a roadmap for putting at the top of national agendas a life-long vaccination approach in Europe, as proposed in the Council conclusions on vaccinations as an effective tool in public health. Our position paper can be accessed here.
Vaccines Europe welcomes the EU Health Council adoption of the Council Conclusions on the next steps under a one health approach to combat antimicrobial resistance. Vaccines Europe believes that a holistic approach that takes into account alternative approaches which can reduce the use of antibiotics should be considered as part of a long term strategy to combat this global public health issue. The Council Conclusions call upon the Member States to “encourage the use of alternative treatment and prevention options including vaccines and the development and use of affordable diagnostics tests in human and veterinary medicine“, which is in line with recent evidence that suggests that antibiotic use can decrease in association with the initiation of immunisation programmes or increased uptake of available vaccines. The Vaccines Europe members are committed to this global health issue by investing in the development of vaccines that target resistant bacteria that causes healthcare associated infections, such as Staphylococcus aureus and Clostridium difficile which would play a crucial role in tackling drug resistance.
Find here a draft Vaccines Europe paper on the Role of vaccination in reducing antimicrobial resistance.